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The relationship between major depressive disorder (MDD) and bipolar disorder (BD) remains controversial. Previous research
has reported differences and similarities in risk factors for MDD and BD, such as predisposing personality traits. For example,
high neuroticism is related to both disorders, whereas openness to experience is specific for BD. This study examined
the genetic association between personality and MDD and BD by applying polygenic scores for neuroticism, extraversion,
openness to experience, agreeableness and conscientiousness to both disorders. Polygenic scores reflect the weighted sum of
multiple single-nucleotide polymorphism alleles associated with the trait for an individual and were based on a meta-analysis of
genome-wide association studies for personality traits including 13 835 subjects. Polygenic scores were tested for MDD in the
combined Genetic Association Information Network (GAIN-MDD) and MDD2000þ samples (N¼ 8921) and for BD in the
combined Systematic Treatment Enhancement Program for Bipolar Disorder and Wellcome Trust Case–Control Consortium
samples (N¼ 6329) using logistic regression analyses. At the phenotypic level, personality dimensions were associated with
MDD and BD. Polygenic neuroticism scores were significantly positively associated with MDD, whereas polygenic extraversion
scores were significantly positively associated with BD. The explained variance of MDD and BD,B0.1%, was highly comparable
to the variance explained by the polygenic personality scores in the corresponding personality traits themselves (between 0.1
and 0.4%). This indicates that the proportions of variance explained in mood disorders are at the upper limit of what could have
been expected. This study suggests shared genetic risk factors for neuroticism and MDD on the one hand and for extraversion
and BD on the other.
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Introduction
The relationship between major depressive disorder (MDD)
and bipolar disorder (BD) remains controversial. Both are
characterized by depressive episodes, whereas BD is, in
addition, characterized by manic episodes.1 Research into risk
factors for MDD and BD reports similarities and differences.
This also applies to studies investigating the association
between personality and MDD or BD. Most of these studies
have focused on the personality traits neuroticism/negative
emotionality (N), extraversion/positive emotionality (E)2,3 and,
to a lesser extent, agreeableness (A), conscientiousness (C)
and openness to experience (O).2 ‘N’ is commonly defined as
a tendency toward emotional instability. ‘E’ is characterized by
a disposition toward positive emotions, gregariousness and
the tendency to be active, seek out stimulation and enjoy the
company of others. ‘O’ involves active imagination, aesthetic
attentiveness, variety preference and intellectual curiosity.
‘A’ can be defined as the tendency to be cooperative and
compassionate rather than suspicious and antagonistic
toward others. Finally, the dimension ‘C’ reflects traits
of self-discipline, carefulness, thoroughness, organization,
deliberation and achievement.2,3
In a recent meta-analysis on the relationship between
personality and MDD, MDD was significantly associated with
higher N and with lower C with a Cohen’s d of 1.33 for N and
0.90 for C.4 The association with C became weaker
(Cohen’s d 0.59) after controlling for N, but remained
significant. Although a negative link between E and MDD has
often been reported, the effect was modest and not significant
in the meta-analysis (Cohen’s d0.62). The associations with
O and A were not significant either.
Studies on the association between personality and BD are
sparser, but have consistently shown higher levels on N and O
and lower levels of C compared with normal controls.5–9 This
suggests that subjects with MDD and BD are similar regarding
N and C and differ regarding O. This is supported by studies
directly comparing personality profiles for MDD and BD.5,6,8,9
All studies showed the same trend with higher O in BD
subjects than in MDD subjects. This was significant in only
one of these studies,6 but the other samples included far fewer
subjects and probably did not have the power to detect the
effect (o100 BD subjects versusB1000 subjects).5,8,9 Most
of these studies have been performed in MDD or BD subjects
in an euthymic phase; thus, the results do not reflect a state
effect of mood on personality.
Mood disorders and personality traits are partly influenced by
genetic risk factors. Heritability estimates areB40% for MDD,
50% for personality traits and between 60 and 90% for BD.10–16
This raises the question whether associations between person-
ality and mood disorders are explained by shared genetic risk
factors. So far, this has only been investigated for MDD. Twin
studies have provided considerable support for overlapping
genetic risk factors influencing N and MDD (reviewed in
Middeldorp et al.17). Fewer twin studies have investigated the
association with other personality traits and MDD suggesting a
smaller, but significant genetic correlation between C and O and
MDD,18 but not between E and MDD.19–22
Genome-wide association (GWA) data also provide an
opportunity to investigate whether traits are influenced by
overlapping genetic risk factors. On the basis of GWA results
for one trait, for instance, neuroticism, performed in one
sample (the discovery sample), a polygenic score is calcu-
lated for each individual in another sample (the target
sample). These polygenic scores are obtained by taking a
set of top single-nucleotide polymorphisms (SNPs), for
example, all SNPs with P-values below 0.1 and multiplying
the individual’s genotypic score (0, 1 or 2) by the effect of the
SNP. If the polygenic scores are significantly related to a
second trait, for instance, MDD, in the target sample, this
indicates that the two traits, namely neuroticism and MDD, are
influenced by overlapping genetic risk factors. In this manner,
a genetic relationship was observed for schizophrenia
and BD23 and for MDD and anxiety.24 In the former study,
polygenic scores based on a GWA study in schizophrenia
explained between 1 and 2% in BD. In the latter
study, polygenic scores based on a MDD GWA study
explainedB2% of the variance in anxiety disorders.
This study investigates the genetic association between the
five personality traits N, E, O, A and C and MDD, as well as
BD. On the basis of the results of a GWA meta-analysis of N,
E, O, A and C in 413 000 subjects,25 individual polygenic
scores were calculated and tested for their effect on case–
control status in 2 combined target MDD samples and in 2
combined target BD samples totaling 8921 and 6329 subjects,
respectively. We first asked whether the genetic association
between N and MDD as found in the twin studies is confirmed
using polygenic score analysis and to what extent the other
personality traits are genetically associated with MDD.
Second, we investigated the genetic relationship between
personality and BD. Finally, we asked what the differences
are between the genetically mediated personality profiles
underlying BD and MDD.
Materials and methods
Subjects, measurement instruments and genotyping
Discovery samples for personality. The GWA meta-analyses
were performed on personality data collected from nine
samples: SardiNIA–Italy,26,27 Erasmus Rucphen Family study
(ERF)–The Netherlands,28 Study of Addiction: Genetics and
Environment (SAGE)–United States of America,29 Helsinki
Birth Cohort Study (HBCS)–Finland,30–32 Nicotin Addiction
Genetics Study/Interactive Research Project Grants (NAG/
IRPG) study–Australia,33,34 Queensland Institute of Medical
Research (QIMR) adolescent study–Australia,35,36 Lothian
Birth Cohort 36 (LBC36)–United Kingdom,37 Baltimore
Longitudinal Study of Aging (BLSA)–United States of
America38 and Estonian Genome Project of University of
Tartu (EGPUT)–Estonia.39 For a detailed description of these
samples, we refer to de Moor et al.25 The total number of
subjects available for the meta-analyses was 13 835. Sample
sizes ranged from 600 to 3972 individuals. Mean age ranged
from 19 to 70 years. In 5 studies, the mean age was between
40 and 50 years, in 1 study the mean age was 19 years, and
in 3 studies, the mean age was between 60 and 70 years. It
must be noted that the meta-analysis as described in de Moor
et al.25 also included the GAIN-MDD sample. This sample
was excluded in the personality traits meta-analyses for this
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study as the GAIN-MDD set served as one of the target
samples (see below for the description of the sample).
Personality scores were assessed with NEO Personality
Inventory–Revised (NEO-PI-R), NEO-PI-3 or the NEO
Five-Factor Inventory.2,40 In each study, scores for the 5 factors
N, E, O, A and C were based on the 60 items of the NEO Five-
Factor Inventory (12 items per phenotype).2 Summed scores
were computed for all five personality dimensions.
DNA was extracted from blood samples. Genotyping was
performed on Illumina platforms (Illumina, San Diego, CA,
USA) in all studies, except in SardiNIA in which an Affymetrix
platform (Affymetrix, Santa Clara, CA, USA) was used.
Genotype data were checked in each study independently,
using slightly different inclusion criteria. Among the basic
checks that were performed are checks for European
ancestry, Mendelian errors, gender inconsistencies and high
genome-wide homozygosity. Genotype data were further
cleaned based on Hardy–Weinberg equilibrium, minor allele
frequencies, SNP call rate (% of subjects with missing
genotypes per SNP) and sample call rate (% of missing SNPs
per subject). Imputation to B2.5 M common SNPs included in
HapMap was performed using the HapMap phase II CEU data
as the reference sample (NCBI build 36/UCSC hg18, Bethesda,
MD, USA). Imputation was carried out using IMPUTE for SAGE
and EGPUT samples.41 For the other samples, genotype data
were imputed using MACH software.42
Target samples for MDD and BD. Polygenic scores were
tested in two MDD case–control samples: GAIN-MDD and
MDD2000þ and in two BD case–control samples: Wellcome
Trust Case–Control Consortium (WTCCC) and Systematic
Treatment Enhancement Program for Bipolar Disorder
(STEP-BD). The four samples have been described in
detail elsewhere.43–48 MDD and BD diagnoses were
assessed with commonly used standardized interviews.
GAIN-MDD. This sample consisted of subjects from two
large-scale longitudinal studies:43,46 the NESDA (Netherlands
Study of Depression and Anxiety)49 and the NTR (Netherlands
Twin Register).50 The mean ages of cases (N¼ 1738) and
controls (N¼ 1802) were 43 and 45 years, respectively.
Inclusion criteria for MDD cases were a lifetime diagnosis of
Diagnostic and Statistical Manual of Mental Disorders 4th
Edition MDD,1 age of 18–65 years and self-reported Western
European ancestry. Inclusion criteria for control subjects were
no report of MDD at any measurement occasion and low
genetic liability for MDD based on survey data measuring
MDD-related traits. In addition, controls and their parents were
required to have been born in the Netherlands or Western
Europe. Only one control per family was selected.
Individual genotyping was conducted by Perlegen Sciences
(Mountain View, CA, USA) using a set of four proprietary, high-
density oligonucleotide arrays. Imputation was carried out
using IMPUTE software41 with the HapMap phase II CEU data
as the reference sample using NCBI build 36 (UCSC hg18).
MDD2000þ . The second MDD target sample consisted of
2101 cases and 3280 screened controls, a subset of the
MDD2000þ sample after excluding samples that overlapped
with the discovery and GAIN-MDD samples.48 Samples were
provided by the Queensland Institute of Medical Research
(QIMR, Brisbane, QLD, Australia), NESDA, NTR, the
University of Edinburgh (UoE, Scotland, UK) and the MGS
(Molecular Genetics of Schizophrenia) study (controls only,
United States). Control subjects from NTR who also
participated in the GAIN-MDD study (N¼ 223) were
excluded, as well as cases and controls from the NAG/
IPRG study that had been included in the personality traits
meta-analysis (N¼ 500). Mean ages of cases and controls
were 41 and 48 years, respectively. MGS controls completed
an online questionnaire including the short-form CIDI,
supplemented by questions about schizophrenia, psychosis
and BD. Controls were required to never have met the criteria
for these disorders or MDD.
Genotyping was conducted on different Illumina and
Affymetrix platforms. Imputation was conducted in four
analysis sets (I317, I370, I610 and A6.0) to a common set of
SNPs present in HapMap3 CEU/TSI, using Beagle 3.04.51,52
Wellcome Trust Case–Control Consortium. The sample
comprises 1868 BD cases.47 They were over the age of 16
years and of European descent. Individuals who had been in
contact with mental health services were recruited if they
suffered from a major mood disorder in which clinically
significant episodes of elevated mood had occurred, such as
bipolar I disorder (71% cases), schizoaffective disorder
bipolar type (15% cases), bipolar II disorder (9% cases)
and manic disorder (5% cases).
Half of the 3000 controls came from the 1958 British Birth
cohort (58C) and were between 44 and 45 years of age at the
time of DNA collection. The other half was selected from blood
donors. Age ranged from 18 to 69 years. Analyses were
carried out on observed genotypes. Ancestry principal
components were available for 3919 subjects (1452 cases
and 2467 controls), and these subjects were included in the
current analyses.
Systematic Treatment Enhancement Program for Bipolar
Disorder. STEP-BD was a US national, longitudinal public
health initiative designed to examine the effectiveness of
treatments and their impact on the course of BD.44,45 Over a
7-year period, 4361 participants were enrolled across 20
sites and followed for up to 2 years. From the parent STEP-
BD study, 2089 individuals were enrolled in a genetic
substudy. Mean age was 43 years. Only non-Hispanic
Caucasian individuals with European ancestry based on
self-reported race and ethnicity information were included.
Controls were used from the NIMH (National Institute of
Mental Health) Genetics Repository and were MGS controls.
This study included 1507 cases with bipolar I and bipolar II
disorder and 903 controls.
Genotyping was performed using the Affymetrix GeneChip
Human Mapping 500K Array Set. Beagle, version 3.1.1 was
used to impute missing genotypes, with HapMap2 (Centre
d’Etude du Polymorphisme Humain from Utah population,
release 23, forward strand) as the reference panel.
Statistical analyses
GWAmeta-analyses of personality. Genome-wide association
meta-analyses were carried out as described in de
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Moor et al.25 without inclusion of the GAIN-MDD data. Meta-
analyses were based on GWA analyses for the five personality
traits conducted in each study with linear regression (under an
additive model) and included sex and age as covariates. Meta-
analyses of the results were conducted by the weighted
inverse variance method as implemented in METAL (http://
www.sph.umich.edu/csg/abecasis/metal/index.html),53 which
computes a pooled effect estimate (ln(beta)), its s.e. and its
P-value by weighing the effect estimates of individual samples
by the inverse of its variance and by taking into account the
direction of effect.
Polygenic score analyses. The genetic associations of the
five personality scales with MDD and BD were analyzed for
each personality scale separately in the combined samples for
MDD and in the combined samples for BD. Polygenic scores
were calculated and tested for their effect according to Purcell
et al.23 Five sets of SNPs were selected from the GWA results
for each of the five NEO personality scales meta-analyses. This
selection of SNPs was based on their nominal P-value
(Pdiscovery) for association with the NEO-personality scale in
the discovery sample. For each of the five personality scales,
five sets of SNPs were selected, one with Pdiscovery threshold
0.1, one with threshold 0.2, one with threshold 0.3, one with
threshold 0.4 and one with threshold 0.5. These sets of SNPs
were used to calculate the polygenic scores for subjects in the
four target samples by multiplying the dosage score of risk
allele count per SNP from 0 to 2 by the beta, summed over all
SNPs in the considered set of SNPs and divided by the total
number of SNPs.23 In short:
P
dosageScore*beta/N(SNPs).
Dosage scores were used to account for the uncertainty in the
imputed genotypes. We calculated individual scores for each
set of SNPs using the PLINK software.54
The association of the polygenic scores with MDD was
evaluated by logistic regression. Ancestry principal compo-
nents were included as covariates. The explained variance
was based on Nagelkerke’s R2. To analyze polygenic scores
in the combined samples (GAIN-MDDþMDD2000þ and
WTCCCþSTEP-BD), polygenic scores were corrected for
ancestry principal components. Next, a logistic regression
with sample as covariate was performed with standardized
residuals of polygenic scores as independent variables.
Results
To illustrate the association between personality dimensions
and MDD or BD, Table 1 shows the scores for five personality
traits measured with the NEO Five-Factor Inventory2 in GAIN-
MDD controls, GAIN-MDD cases and STEP-BD cases at entry
to the study. Four of the five personality scales were significantly
different in MDD patients compared with controls: N scores were
higher, whereas A, E and C scores were lower in depressed
subjects (all P-values o0.0001 in a t-test). As described in
Barnett et al.,6 BD patients at a euthymic phase significantly
differed from the population norms for all scales exhibiting higher
levels of N and O and lower levels of E, C and A.
The sets of SNPs with P-values below 0.1, 0.2, 0.3, 0.4 and
0.5 based on the results in the discovery sample included the
number of SNPs as expected for these P-values, that is,
B200 k, 400 k, 600 k, 800 k and 1 million SNPs, respectively.
The overlap with SNPs used to calculate polygenic scores in
the target samples was 100% for the GAIN-MDD sample, 40%
for the MDD2000þ sample, 20% for the WTCCC sample and
90% for the STEP-BD sample. The lower overlap is due to the
use of HapMap 3 as a reference set in the MDD2000þ
sample and to the use of observed genotypes only in the
WTCCC sample.
Figure 1 presents the results of the logistic regression
analysis for MDD with the personality polygenic scores based
on the GWA meta-analysis as independent variables.
Significant positive associations were found between MDD
and polygenic N scores for all sets of SNPs. In addition,
significant negative associations were found between MDD
and polygenic E scores based on the sets of SNPs with
P-values o0.1 and o0.5 and polygenic C scores based on
the sets of SNPs with P-valueso0.3 too0.5. These effects
explained 0.1% of the variance in MDD (P-valueo0.05).
Figure 2 shows results of the logistic regression analysis for
BD. Polygenic E scores were significantly positively related to
BD, explaining 0.1% of the variance (P-valueo0.05).
The analyses were also carried out in the four samples
separately to check for heterogeneity in the results across
studies. None of the polygenic personality scores were
significantly associated with MDD in the MDD2000þ study
with the proportion of explained variance always below 0.1%.
This is in contrast to the analyses of the GAIN-MDD sample in
which polygenic N scores based were significantly higher in
MDD cases than in controls, explaining between 0.2 and 0.4%
of the variance (P-values o0.005) (see Supplementary
Figure 1a). Moreover, polygenic C scores, based on the sets
of SNPs with P-values o0.3 and o0.5, were lower in MDD
cases explaining 0.2 and 0.3% of the variance (P-values
Table 1 Mean (s.d.) neuroticism (N), extraversion (E), agreeableness (A),
openess to experience (O) and conscientiousness scores (C) in GAIN-MDD
controls and GAIN-MDD cases and STEP-BD cases
Controls MDD BD
N 14.6 (5.9) 27.3 (8.1)* 30.9 (8.6)**
E 30.5 (5.7) 23.1 (7.0)* 23.2 (7.5)**
A 33.4 (4.7) 31.4 (5.4)* 29.9 (6.9)**
O 25.0 (5.7) 24.8 (5.6) 29.5 (7.0)**
C 33.5 (4.8) 25.6 (6.1)* 26.8 (8.0)**
Abbreviations: BD, bipolar disorder; MDD, major depressive disorder; STEP-
BD, Systematic Treatment Enhancement Program for Bipolar Disorder.
*Po0.00001 compared with GAIN-MDD controls.
**Po0.001 compared with population norms.6
Figure 1 Explained variance by the five personality traits polygenic scores in
MDD in GAIN-MDD þ MDD2000þ , *Po0.05. MDD, major depressive disorder.
Personality and depression or BD
CM Middeldorp et al
4
Translational Psychiatry
o0.05). Thus, the significant results for MDD are mostly
driven by the GAIN-MDD study.
The picture looks different for BD (see Supplementary
Figures 1b and 1c). In the STEP-BD sample, polygenic
E scores based on the sets of SNPs with P-valueso0.4 and
0.5 and polygenic C scores based on the sets of SNPs with
P-values o0.1 showed a significant positive and negative
association, respectively, with BD. There were no significant
effects detected in WTCCC, but the proportion of explained
variance by polygenic E scores is similar as in the STEP-BD
study. This suggests that, although separate studies are
sometimes underpowered to detect the small effects of
polygenic E scores, they both contribute to the significant
effects as found in the analyses of the combined samples.
Given the relatively low proportion of variance explained
by the polygenic personality scores for mood disorders,
additional regression analyses were performed to detect the
proportion of variance explained by the polygenic personality
scores in the personality trait scores themselves. It was tested
whether the polygenic N, E, O, A and C scores, as used in the
analyses above, significantly predicted the respective N, E, O,
A and C trait scores as measured in GAIN-MDD subjects. The
polygenic scores explained between 0.1 and 0.4% of
the corresponding personality trait scores (P-values between
0.0003 and 0.2) with the best results for polygenic O scores
predicting O and the worst results for polygenic A scores
predicting A.
Discussion
This study suggests that MDD is influenced by similar genetic
risk factors as neuroticism (N) and that BD is influenced
by similar genetic risk factors as extraversion (E). Both
associations are positive: that is, genetic risk factors related to
a higher N score increase the risk for MDD and genetic risk
factors related to a higher E score increase the risk for BD.
Moreover, genetic risk factors influencing conscientiousness
(C) and E might be negatively associated with MDD, but
results are less consistent.
The results for MDD agree with earlier genetic epidemio-
logical research. Several studies have already suggested an
overlap in genetic risk factors for neuroticism and MDD as
reviewed by Middeldorp et al.17 A negative genetic correlation
between MDD and C has also been reported.18
The genetic relationship between personality and BD has
not been investigated before. With the exception of E,
the absence of a genetic association between personality
traits and BD is surprising given the phenotypic relationships
between BD and the five personality traits found in the STEP-
BD sample (Table 1) and other studies.5–9 Furthermore,
the genetic association with E was positive, whereas the
phenotypic association found in the total sample of STEP-BD
subjects was negative. However, Barnett et al.6 showed in
the same study sample that high N was related to
a depression-prone BD course, whereas high E was related
to a manic-prone BD course. Similar findings were reported by
Quilty et al.55
The explained variance in MDD and BD by the polygenic
scores was very modest. However, this was also true for
prediction of the personality traits themselves with compar-
able proportions of explained variance (up to 0.4%) and
P-values. Thus, the proportions of explained variance for
mood disorders are at the upper limit of what could have been
expected. Still, these numbers are lower than the explained
variance ofB2% reported for polygenic schizophrenia scores
predicting BD and polygenic MDD scores predicting anxiety
disorders.23,24 This can be partly explained by a lack of power.
Although the discovery sample was large with 413 000
subjects, only a few SNPs reached genome-wide significance
and the deviation of the line of observed P-values from the line
of expected P-values in the QQ plots is also modest.25 As the
individual effect sizes of SNPs are small, the error of the
estimates is relatively large. Therefore, the explained variance
in a prediction analysis is low.56 This is comparable to the
results of the analyses of GWA data for intelligence, which
showed that the proportion of variance explained by all SNPs
varied between 40 and 51%, whereas prediction analyses
only explained 1% of the variance in intelligence.57
An additional explanation could be the large age differences
in the studies included in the discovery set, resulting in top hits
in the meta-analysis that reflect genetic variants associated
with stability in personality traits from adolescence through
older age. It is possible that genetic risk factors influencing
stability over time are less related to MDD and BD than genetic
risk factors for personality that are mostly important around
early adulthood, the period of onset of MDD and BD. However,
longitudinal twin studies suggest that genetic influences on
personality are for the largest part stable, thus without much
change in genetic risk factors across time (see, for example,
Kandler et al.58 for a study in adults and Gillespie et al.59 and
Hopwood et al.60 for studies in adolescents and young adults).
A strength of our study, on the other hand, is that polygenic
scores were determined from GWA study results in a sample
of individuals without mood disorders and are not confounded
by mood state in the cases.
The STEP-BD sample and the MDD2000þ sample both
included MGS controls. That is no problem as the discovery
sample and target samples were not overlapping.
Analyses of the effects of the polygenic personality scores
on mood disorders in the four separate studies indicated that
for BD, results were consistent over studies, whereas for
MDD, results were mainly driven by the GAIN-MDD study.
There does not seem to be an obvious explanation for the
absence of effect in the MDD2000þ sample. The overlap in
Figure 2 Explained variance by the five personality traits polygenic scores in BD
STEP-BDþWTCCC, *Po0.05. BD, bipolar disorder; STEP-BD, Systematic
Treatment Enhancement Program for Bipolar Disorder; WTCCC, Wellcome Trust
Case–Control Consortium.
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SNPs used to calculate polygenic scores was far lower in the
MDD2000þ sample than in the GAIN-MDD sample because
of the use of different reference sets for the imputation,
HapMap3 in MDD2000þ and HapMap2 in MDD-GAIN.
HapMap3 includes less SNPs but is based on more subjects.
However, the overlap in SNPs was also lower in the WTCCC
sample, whereas their results were similar to the results in the
STEP-BD sample, which had a high overlap in SNPs.
Therefore, the low overlap in SNPs does not seem to explain
the difference in results between the MDD2000þ and the
MDD-GAIN sample. Given the repeatedly found genetic
correlation between N and MDD, it seems most likely that
the finding in MDD2000þ is a false negative finding.
Despite the low explained variance, the results of this study
indicate some interesting issues regarding the etiology of
MDD and especially BD. Although studies investigating the
phenotypic association between personality and MDD, as well
as BD suggest that both disorders are related to high N and
that, in addition, BD is related to high O, the genetic
association shows a different picture of shared genetic risk
factors for N and MDD on the one hand and for E and BD on
the other. As previous studies have already pointed to
differences in personality profiles between depression-prone
and manic-prone BD patients,6,55 these results imply that BD
is a heterogeneous disorder with different expressions related
to different, genetically influenced, personality profiles. This
view is supported by the finding that an association with
polymorphisms in the GABA receptor b1 subunit gene is most
significant in cases fulfilling the Research Diagnostic Criteria
for schizo-affective disorder. Cases fulfilling the Research
Diagnostic Criteria for Bipolar Disorder type II showed
a similar allele frequency as did controls.61 Future studies in
larger samples, for example, the Psychiatric GWAS
Consortium62 are suited to further investigate the complex
association between personality and BD. For MDD, the
genetic association with N is now well established as studies
using different methods reveal similar results. This is
beneficial for molecular genetic studies as statistical
power can be increased by performing bivariate association
analyses of neuroticism and MDD.
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